KEVA FOTHERGILL: Open Payments
NPI 1285793935 · NORWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,339 in 111 payments from 25 companies in 2025. Trend: 2023 $2,450 · 2024 $2,203 · 2025 $2,339
Food & beverage: $2,339
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 21 | $255 |
| Lilly USA, LLC | 5 | $242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $217 |
| AstraZeneca Pharmaceuticals LP | 8 | $201 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $196 |
| GlaxoSmithKline, LLC. | 13 | $192 |
| Lundbeck LLC | 5 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $126 |
| ABBVIE INC. | 6 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $108 |
Products named: Dexcom G6 Transmitter, TRINTELLIX, Kerendia, TRELEGY ELLIPTA, REXULTI, FARXIGA, CAPLYTA, FANAPT.
Industry payments across CT — which companies pay providers there.
